Furthermore, preclinical studies have revealed that Clostridium butyricum treatment of colorectal cancer cells result in MYC degradation through increased proteasome-mediated ubiquitination, thereby enhancing the anti-PD-1 immunotherapeutic efficacy [29]. Here, MYC is linked to colorectal cancer.